GPs have an important role to play in ensuring that all infants are protected from RSV infection.
While many newborns are already protected, either through the Maternal RSV Immunisation Program or via a birth dose of Beyfortus (nirsevimab) in hospital, some babies are falling through the cracks.
It is crucial that GPs check infants’ immunisation status at their six-week appointment and offer immunisation with the monoclonal antibody Beyfortus (nirsevimab) if eligible. The clinical decision aid for Beyfortus can support GPs in identifying eligible patients.
Factors that can result in babies having missed out on RSV protection prior to the six-week appointment include:
RSV immunisation is proven to significantly reduce infant hospitalisations
The first year of Australia’s maternal and infant RSV program resulted in a 43.8% reduction in RSV hospitalisations among infants younger than 3 months, the age group at highest risk of severe disease.
Infants whose mothers received an RSV vaccine during pregnancy were 80% less likely to be hospitalised with RSV, while infants who received Beyfortus (nirsevimab) were 90% less likely to be hospitalised, compared with infants who received neither form of protection.
Prior to the implementation of the RSV program, around one in 50 children required hospitalisation due to RSV in their first year of life.
Ensure that you check infants’ RSV immunisation status at their six-week appointment and offer Beyfortus (nirsevimab) if eligible.
Immunisation Weekly Update: Capvaxive stock exhausted Current stocks of Capvaxive have been exhausted due to ongoing supply and distribution constraints, resulting in a temporary vaccine shortage. Further stock is anticipated to arrive in the coming weeks. Please ensure clinics or appointments for eligible patients are only booked when you have…
Immunisation Weekly Update: Capvaxive® supply constraints General practices are advised that there are currently national supply delays affecting Capvaxive® (adult pneumococcal vaccine). To help manage available stock, practices should only schedule vaccination appointments for eligible patients when adequate vaccine supplies are available on site. Supply constraints are expected to improve…
Immunisation Weekly Update: NSW Health Vaxigrip stock exhausted: temporary stock-sharing licence in place As of 20 July 2026, NSW Health has exhausted its available stock of Vaxgrip vaccine, which is funded for people aged 6 months to less than 5 years under the National Immunisation Program (NIP). NSW Health has…
Immunisation Weekly Update: Diphtheria vaccination for Aboriginal people and travellers Child vaccination FAQ resource Fatal meningococcal Y case in WA Education Diphtheria vaccination for Aboriginal people and travellers Recent diphtheria outbreaks in parts of Australia have prompted ATAGI to release updated advice regarding vaccination in outbreak settings. Clinicians should check…
Immunisation Weekly Update: Co-administration of vaccines guide The NCIRS Co-administration of vaccines guide for immunisation providers was updated July 2026. Most vaccines can be co-administered with other vaccines at the same National Immunisation Program (NIP) schedule point. Separate injection sites should be used where possible, and if the same muscle…
